title: Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
abstract: Chk2 is a protein kinase involved in the ATM-dependent checkpoint pathway (http://discover.nci.nih.gov/mim). This pathway is activated by genomic instability and DNA damage and results in either cell cycle arrest, to allow DNA repair to occur, or cell death (apoptosis). Chk2 is activated by ATM-mediated phosphorylation and autophosphorylation and in turn phosphorylates its downstream targets (Cdc25A, Cdc25C, BRCA1, p53, Hdmx, E2F1, PP2A, and PML). Inhibition of Chk2 has been proposed to sensitize p53-deficient cells as well as protect normal tissue after exposure to DNA-damaging agents. We have developed a drug-screening program for specific Chk2 inhibitors using a fluorescence polarization assay, immobilized metal ion affinity-based fluorescence polarization (IMAP). This assay detects the degree of phosphorylation of a fluorescently linked substrate by Chk2. From a screen of over 100,000 compounds from the NCI Developmental Therapeutics Program, we identified a bis-guanylhydrazone [4,4'-diacetyldiphenylureabis(guanylhydrazone); NSC 109555] as a lead compound. In vitro data show the specific inhibition of Chk2 kinase activity by NSC 109555 using in vitro kinase assays and kinase-profiling experiments. NSC 109555 was shown to be a competitive inhibitor of Chk2 with respect to ATP, which was supported by docking of NSC 109555 into the ATP binding pocket of the Chk2 catalytic domain. The potency of NSC 109555 was comparable with that of other known Chk2 inhibitors, such as debromohymenialdisine and 2-arylbenzimidazole. These data define a novel chemotype for the development of potent and selective inhibitors of Chk2. This class of drugs may ultimately be useful in combination with current DNA-damaging agents used in the clinic.
authors.affiliation: Laboratory of Molecular Pharmacology, Bldg 37, Rm 5068, National Institutes of Health, Bethesda, MD 20892-4255. pommier@nih.gov.
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Jobson
authors.forename: John H
authors.initials: JH
authors.lastname: Cardellina
authors.forename: Dominic
authors.initials: D
authors.lastname: Scudiero
authors.forename: Sudhir
authors.initials: S
authors.lastname: Kondapaka
authors.forename: Hongliang
authors.initials: H
authors.lastname: Zhang
authors.forename: Hijoo
authors.initials: H
authors.lastname: Kim
authors.forename: Robert
authors.initials: R
authors.lastname: Shoemaker
authors.forename: Yves
authors.initials: Y
authors.lastname: Pommier
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D002224:Carbanilides / Q000494:pharmacology*; D020134:Catalytic Domain; D064447:Checkpoint Kinase 2; D016231:Fluorescence Polarization Immunoassay; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors
chemical_list: D002224:Carbanilides; D047428:Protein Kinase Inhibitors; D011994:Recombinant Proteins; C100261:diacetyldiphenylurea bisguanylhydrazone; D000255:Adenosine Triphosphate; D064447:Checkpoint Kinase 2; D017346:Protein Serine-Threonine Kinases